Local view for "http://purl.org/linkedpolitics/eu/plenary/2005-07-04-Speech-1-130"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20050704.18.1-130"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
".
Mr President, we have been warned by the World Health Organisation that global cancer rates could increase by 50% to 50 million new cases by 2020. With cancer rates across the world growing at this phenomenal rate, citizens are depending on governments for help, protection and information. Phthalates, as we now know, are used in large quantities. In some cases, a proportion of up to 45% is used to increase the pliability of toys or childcare articles made from plasticised material.
I support the legislation, but before welcoming the compromise package agreed between the representatives of the European Parliament and the Council, which goes further by extending the ban of concentration in toys and childcare articles to children in general – as opposed to the original wording referring to children under three years of age – we must first obtain clarification as to the exact nature of the risk posed by DINP, DIDP and DNOP to children. I note that there are divergent opinions as to the danger they pose and would appreciate clarification to that effect as soon as possible.
I congratulate the rapporteur, Mr Trakatellis, on the balance of this report and support the general call for more labelling and information for the consumer. I also agree that more research is required to take account of the exposure of children to risks from sources other than toys.
In addition, we should certainly be researching into restrictions on the marketing and use on the European market of dangerous substances to which newborn babies, children, pregnant women, elderly persons, workers and other high-risk sections of the population are heavily exposed.
In conclusion, we should also be encouraging the production of safer medical alternatives and encouraging their markets as they become available."@en1
|
| lpv:spokenAs | |
| lpv:unclassifiedMetadata |
Named graphs describing this resource:
The resource appears as object in 2 triples